Twist Bioscience Corp
NASDAQ:TWST
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Twist Bioscience Corp
NASDAQ:TWST
|
2.5B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.8B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Twist Bioscience Corp
Glance View
In the bustling world of biotechnology, Twist Bioscience Corp. has emerged as a trailblazer with its innovative approach to DNA synthesis technology. Founded on the premise of leveraging the power of synthetic DNA, Twist has unraveled the potential of precision engineering in genetics. The company operates with a unique silicon-based DNA synthesis platform, which allows for the rapid and cost-effective production of high-quality DNA. This cutting-edge technology facilitates advancements in various domains such as drug development, agricultural biology, and data storage. By addressing the ever-growing demand for synthesized DNA across these sectors, Twist positions itself at the intersection of technology and life sciences, offering a robust solution that fuels the DNA-driven innovations of tomorrow. At its core, Twist Bioscience generates revenue by providing its customers with a streamlined supply of custom DNA products, catering to researchers and businesses that require precise genetic sequences with high fidelity. This includes synthetic genes, oligonucleotide pools, and libraries used for CRISPR screening and other applications. The company has strategically diversified its offerings to include specialized DNA libraries and biopharmaceutical solutions, further extending its reach into therapeutic discovery and development. By aligning its business model with the needs of its clients, Twist ensures consistent growth by capitalizing on the expanding markets of biotechnology and synthetic biology, turning its pioneering technological capabilities into a profitable enterprise.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Twist Bioscience Corp is -20.6%, which is above its 3-year median of -67.7%.
Over the last 3 years, Twist Bioscience Corp’s Net Margin has increased from -107% to -20.6%. During this period, it reached a low of -107% on Sep 30, 2022 and a high of -20.6% on Sep 30, 2025.